These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37602356)

  • 21. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
    Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
    Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable
    Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.
    Scarsi KK; Havens JP; Podany AT; Avedissian SN; Fletcher CV
    Drugs; 2020 Nov; 80(16):1649-1676. PubMed ID: 32860583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors.
    Hoffmann C; Llibre JM
    AIDS Rev; 2019; 21(1):4-10. PubMed ID: 30899113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.
    Dow DE; Bartlett JA
    Infect Dis Ther; 2014 Dec; 3(2):83-102. PubMed ID: 25134686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
    Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
    J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic drug interactions of integrase strand transfer inhibitors.
    Lu CH; Bednarczyk EM; Catanzaro LM; Shon A; Xu JC; Ma Q
    Curr Res Pharmacol Drug Discov; 2021; 2():100044. PubMed ID: 34909672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
    Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R;
    Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
    Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
    J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in the weight, gained due to dolutegravir, following switch to bictegravir.
    Saple D; Save S; Powar I
    Indian J Sex Transm Dis AIDS; 2022; 43(1):27-29. PubMed ID: 35846543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis.
    Kajogoo VD; Amogne W; Medhin G
    Metabol Open; 2023 Mar; 17():100235. PubMed ID: 36923992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
    Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
    Smith SJ; Zhao XZ; Burke TR; Hughes SH
    Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of depression and suicidal behaviour reporting with HIV integrase inhibitors: a global pharmacovigilance study.
    Préta LH; Chroboczek T; Treluyer JM; Chouchana L
    J Antimicrob Chemother; 2023 Aug; 78(8):1944-1947. PubMed ID: 37311223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
    Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
    J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men.
    Haaland RE; Fountain J; Martin A; Dinh C; Holder A; Edwards TE; Lupo LD; Hall L; Conway-Washington C; Massud I; García-Lerma JG; Kelley CF; Heneine WM
    J Antimicrob Chemother; 2023 Feb; 78(2):497-503. PubMed ID: 36512383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.